Department of Psychiatry and Psychotherapy, University of Goettingen, Goettingen, Germany.
World J Biol Psychiatry. 2012 Jul;13(5):318-78. doi: 10.3109/15622975.2012.696143.
These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry Guidelines for Biological Treatment of Schizophrenia published in 2005. For this 2012 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations that are clinically and scientifically meaningful and these guidelines are intended to be used by all physicians diagnosing and treating people suffering from schizophrenia. Based on the first version of these guidelines, a systematic review of the MEDLINE/PUBMED database and the Cochrane Library, in addition to data extraction from national treatment guidelines, has been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into six levels of evidence (A-F; Bandelow et al. 2008b, World J Biol Psychiatry 9:242). This first part of the updated guidelines covers the general descriptions of antipsychotics and their side effects, the biological treatment of acute schizophrenia and the management of treatment-resistant schizophrenia.
这些更新后的指南是基于世界生物精神病学学会 2005 年发布的第一版《精神分裂症生物治疗指南》。为了进行 2012 年的修订,对所有与精神分裂症生物治疗相关的现有出版物进行了系统审查,以进行基于证据的更新。这些指南提供了具有临床和科学意义的循证实践建议,旨在供所有诊断和治疗精神分裂症患者的医生使用。基于这些指南的第一版,对 MEDLINE/PUBMED 数据库和 Cochrane 图书馆进行了系统审查,并对国家治疗指南进行了数据提取,以进行本次更新。根据其疗效的证据强度对确定的文献进行了评估,然后将其分为六个证据级别 (A-F; Bandelow 等人,2008b,《世界生物精神病学杂志》9:242)。本更新指南的第一部分涵盖了抗精神病药物及其副作用的一般描述、急性精神分裂症的生物治疗以及治疗抵抗性精神分裂症的管理。